Related Experiment Video
Updated: May 31, 2026
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Initial clinical experience with RADA16 as a novel therapeutic for severe haemorrhagic radiation cystitis: a
Petre Cristian Ilie1, Anne Carrie2, Yacine Touati3
1Urology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK. petre.ilie@nnuh.nhs.uk.
Background:
Haemorrhagic radiation cystitis (HRC) is a challenging complication of pelvic radiotherapy, often resistant to conventional treatments.
Aims:
To evaluate the clinical efficacy and safety of RADA16, a self-assembling peptide, in managing severe HRC.
Methods:
A preliminary feasibility case series of five consecutive patients treated at two UK hospitals. All patients had persistent haematuria despite standard interventions and received RADA16 via flexible or rigid cystoscopy.
Results:
The findings from the cases suggest that all patients have experienced at least a partial or early resolution of haematuria and no adverse effects were reported. In most cases, two applications of RADA16 were sufficient. The longest patient followed up was still symptom free at 3 years.
Discussion:
This preliminary feasibility case series has demonstrated early efficacy for RADA16 in the management of HRC.
Conclusions:
RADA16 is a potentially promising minimally invasive treatment for refractory HRC. Further trials are warranted to confirm these findings.
